Suven Life Sciences Limited SUVEN.BO Stock
Suven Life Sciences Limited Price Chart
Suven Life Sciences Limited SUVEN.BO Financial and Trading Overview
| Suven Life Sciences Limited stock price | 112.6 INR |
| Previous Close | 63.72 INR |
| Open | 63.19 INR |
| Bid | 65.04 INR x 0 |
| Ask | 65.36 INR x 0 |
| Day's Range | 63.19 - 66.6 INR |
| 52 Week Range | 45.01 - 84.85 INR |
| Volume | 44.04K INR |
| Avg. Volume | 24.65K INR |
| Market Cap | 14.41B INR |
| Beta (5Y Monthly) | 1.628767 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.77 INR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | February 14, 2019 |
| 1y Target Est | 292 INR |
SUVEN.BO Valuation Measures
| Enterprise Value | 12.59B INR |
| Trailing P/E | N/A |
| Forward P/E | 5.562181 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 106.431305 |
| Price/Book (mrq) | 4.1110554 |
| Enterprise Value/Revenue | 93.01 |
| Enterprise Value/EBITDA | -9.947 |
Trading Information
Suven Life Sciences Limited Stock Price History
| Beta (5Y Monthly) | 1.628767 |
| 52-Week Change | -10.0000024% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 84.85 INR |
| 52 Week Low | 45.01 INR |
| 50-Day Moving Average | 56.94 INR |
| 200-Day Moving Average | 62.11 INR |
SUVEN.BO Share Statistics
| Avg. Volume (3 month) | 24.65K INR |
| Avg. Daily Volume (10-Days) | 20.6K INR |
| Shares Outstanding | 218.07M |
| Float | 61.5M |
| Short Ratio | N/A |
| % Held by Insiders | 72.06% |
| % Held by Institutions | 2.52% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 4:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2023 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | March 31, 2024 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -978.10% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -33.31% |
| Return on Equity (ttm) | -50.17% |
Income Statement
| Revenue (ttm) | 135.39M INR |
| Revenue Per Share (ttm) | 0.76 INR |
| Quarterly Revenue Growth (yoy) | -39.70% |
| Gross Profit (ttm) | 135.39M INR |
| EBITDA | -1266009984 INR |
| Net Income Avi to Common (ttm) | -1182678016 INR |
| Diluted EPS (ttm) | -6.63 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 2.35B INR |
| Total Cash Per Share (mrq) | 9.96 INR |
| Total Debt (mrq) | 16.05M INR |
| Total Debt/Equity (mrq) | 0.43 INR |
| Current Ratio (mrq) | 22.605 |
| Book Value Per Share (mrq) | 15.884 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -1031481984 INR |
| Levered Free Cash Flow (ttm) | -766326976 INR |
Profile of Suven Life Sciences Limited
| Country | India |
| State | N/A |
| City | Hyderabad |
| Address | 8-2-334, SDE Serene Chambers |
| ZIP | 500034 |
| Phone | 91 40 2354 1142 |
| Website | https://www.suven.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities (NCEs) in central nervous system therapies. Its product candidates include SUVN-502 for the treatment of Alzheimer's disease and neuropsychiatric symptoms; SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist for the treatment of depressive disorders. The company is also developing SUVN-D4010, a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders and schizophrenia; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.
Q&A For Suven Life Sciences Limited Stock
What is a current SUVEN.BO stock price?
Suven Life Sciences Limited SUVEN.BO stock price today per share is 112.6 INR.
How to purchase Suven Life Sciences Limited stock?
You can buy SUVEN.BO shares on the BSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Suven Life Sciences Limited?
The stock symbol or ticker of Suven Life Sciences Limited is SUVEN.BO.
Which industry does the Suven Life Sciences Limited company belong to?
The Suven Life Sciences Limited industry is Drug Manufacturers-Specialty & Generic.
How many shares does Suven Life Sciences Limited have in circulation?
The max supply of Suven Life Sciences Limited shares is 221.56M.
What is Suven Life Sciences Limited Price to Earnings Ratio (PE Ratio)?
Suven Life Sciences Limited PE Ratio is now.
What was Suven Life Sciences Limited earnings per share over the trailing 12 months (TTM)?
Suven Life Sciences Limited EPS is -4.77 INR over the trailing 12 months.
Which sector does the Suven Life Sciences Limited company belong to?
The Suven Life Sciences Limited sector is Healthcare.